CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Germany's Medios 9M EBITDA pre falls on price declines

By Reuters News


Overview

  • Germany specialty pharma provider's 9M 2026 revenue rose 6.7% yr/yr

  • EBITDA pre fell 5.2% as profitability was impacted by price declines and higher material costs

  • Company confirmed full-year forecast, expects EBITDA pre at lower end of guidance


Outlook

  • Medios sees 2026 revenue between €2.10 bln and €2.16 bln

  • Company expects 2026 EBITDA pre at the lower end of €88 mln to €92 mln range

  • Company expects Hilfstaxe adjustment to reduce Q4 EBITDA pre by about €1.2 mln


Result Drivers

  • PRICE PRESSURE & COSTS - Co said profitability was hurt by price declines in Pharmaceutical Supply and higher material costs in International Business

  • EFFICIENCY PROGRAM - Co said its 'Avanti Medios!' efficiency measures contributed to improved margins in Patient-Specific Therapies

  • SEGMENT GROWTH - Co said revenue growth was driven by all operating segments


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

9M Revenue

EUR 1.63 bln

9M Cash Flow from Operating Activities

EUR 26.20 mln

9M EBITDA

EUR 66.70 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Medios AG is €20.00, about 75.4% above its November 9 closing price of €11.40

  • The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 9 three months ago


Reuters Recommended Reads

  • Nov 9 - Biopharma Almirall 9M sales rise on European dermatology growth

  • Nov 9 - US FDA approves Bayer's blood thinner to prevent repeat strokes

  • Nov 9 - UK's Mereo BioPharma Q3 revenue beats expectations


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.